This module uses fundamental data of FibroBiologics, Common to approximate the value of its Beneish M Score. FibroBiologics, Common M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out FibroBiologics, Common Piotroski F Score and FibroBiologics, Common Altman Z Score analysis.
FibroBiologics,
Beneish M Score
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Cash Per Share
Pocfratio
Interest Coverage
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Shareholders Equity Per Share
Debt To Equity
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Cash Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Free Cash Flow
Other Cashflows From Financing Activities
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
Change In Cash
Stock Based Compensation
Change In Working Capital
Begin Period Cash Flow
Depreciation
Issuance Of Capital Stock
End Period Cash Flow
Retained Earnings
Common Stock Shares Outstanding
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Lease Obligations
Other Current Assets
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Net Working Capital
Short Term Debt
Depreciation And Amortization
Selling General Administrative
Other Operating Expenses
Operating Income
Research Development
Total Operating Expenses
Income Before Tax
Net Interest Income
Interest Expense
Net Income From Continuing Ops
Ebitda
Reconciled Depreciation
Total Other Income Expense Net
Probability Of Bankruptcy
At this time, FibroBiologics, Common's Debt To Equity is most likely to increase slightly in the upcoming years. The FibroBiologics, Common's current Interest Debt Per Share is estimated to increase to 0.1, while Short and Long Term Debt is projected to decrease to roughly 3.7 M. At this time, FibroBiologics, Common's PB Ratio is most likely to increase significantly in the upcoming years. The FibroBiologics, Common's current Cash Per Share is estimated to increase to 0.27, while Operating Cash Flow Per Share is projected to decrease to (0.24).
At this time, it appears that FibroBiologics, Common is an unlikely manipulator. The earnings manipulation may begin if FibroBiologics, Common's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by FibroBiologics, Common executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of FibroBiologics, Common's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
FibroBiologics, Common Beneish M-Score Indicator Trends
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if FibroBiologics, Common's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
FibroBiologics, Common Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between FibroBiologics, Common's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards FibroBiologics, Common in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find FibroBiologics, Common's degree of accounting gimmicks and manipulations.
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Depreciation And Amortization
453,334
At this time, FibroBiologics, Common's Depreciation And Amortization is most likely to decrease significantly in the upcoming years.
About FibroBiologics, Common Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze FibroBiologics, Common Stock's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of FibroBiologics, Common using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of FibroBiologics, Common Stock based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
When determining whether FibroBiologics, Common is a strong investment it is important to analyze FibroBiologics, Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics, Common's future performance. For an informed investment choice regarding FibroBiologics, Stock, refer to the following important reports:
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.55)
Return On Assets
(0.66)
Return On Equity
(2.68)
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.